Intracoronary mesenchymal stem cell or endothelial progenitor cell transfer post myocardial infarction prevents negative remodeling but fails to enhance global functional recovery
CL Dubois, Stefan Janssens(Maastricht University), Melissa Swinnen(KU Leuven), Frederik Maes(Universitair Ziekenhuis Leuven), Hélène Depelteau(Universitair Ziekenhuis Leuven), Xiaoshun Liu(Vlaams Instituut voor Biotechnologie), Glenn Marsboom(Johnson & Johnson (United States)), Frans Van de Werf(KU Leuven), Lertlak Chaothawee(Universitair Ziekenhuis Leuven), Marijke Pellens(Ghent University), Daisy Thijs, Witold Streb, Désiré Collen(Ghent University), Hilde Gillijns(Ghent University)
Journal of the American College of Cardiology
February 1, 2006
Cited by 1
Related Papers
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
|Nature|1996|4.2k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
|New England Journal of Medicine|2013|1.5k